PBC, PSC & NASH: AASLD Symposium

Register for
PBC, PSC & NASH - Point/Counterpoint Debates

October 30, 2006• 7:00 P.M. – 9:00 P.M.
Sheraton Boston Hotel • Republic Ballroom

6:30 P.M.

Registration and Dinner

7:00 P.M.

Program Introduction
Douglas R. LaBrecque, MD; Program Chair

7:10 P.M.

Debate #1: Is Ursodeoxycholic Acid Really Effective
Therapy in Cholestatic Liver Diseases?
Claudia O. Zein, MD
Marlyn Mayo, MD

7:55 P.M.

Debate #2: Do We Understand the Pathophysiology
of NASH Sufficiently to Define Therapy?
Stephen A. Harrison, MD
Anna Mae Diehl, MD

8:40 P.M.

Q & A

8:55P.M.

Summary and Conclusion

Program Registration
Required First Name
Last Name*
Credentials
Specialty
E-mail:*
Address 1
Address 2
City
State
Zip
Country
Phone
Fax

Continuing Education Information

Intended Audience
This activity is intended for physicians involved in the management of liver disorders.

Program Objectives
The main objective of the symposium is to provide the attendees an opportunity to increase their knowledge of Primary BiliaryCirrhosis (PBC), Primary Sclerosing Colangitis (PSC), and Nonalcoholic Steatohepatitis (NASH) in order to enhance the appropriate management of patients with these diseases. After attending this symposium, the participants should be able to:

Describe the role of ursodeoxycholic acid in the treatment of PBC, PSC and Overlap Syndrome
Summarize the definition of Overlap Syndrome, the validity of such a diagnosis and approaches to its treatment
Cite the current approaches to the diagnosis and management of NASH

CME Accreditation/Credit
The University of Iowa Roy J. and Lucille A. Carver College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians. The University of Iowa Carver College of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits.™ Physicians should only claim credit commensurate withthe extent of their participation in the activity.

Commercial Support
We gratefully acknowledge financial support of this educational activity through an unrestricted educational grant from Axcan Scandipharm Inc.

Note: Determination of this activity's educational content and the selection of speakers are responsibilities of the chairman. The firm providing support did not have input into these areas.

Disclosure Policy
Everyone in a position to control the content of this educational activity will disclose to the CME provider (University of Iowa Carver College of Medicine) and to attendees all relevant financial relationships with any commercial interests. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by
the U.S. Food and Drug Administration (FDA).

Program coordination provided by Zephyr Medical Enterprises of Encino, California.

Presented for attendees of the 57th AASLD Annual Meeting. This event/function is sponsored by University of Iowa Roy J. and Lucille A. Carver College of Medicine and supported by Axcan Scandipharm Inc. This is not an official function/event of the American Association for the Study of Liver Diseases.